Accelerating glioblastoma therapeutics via venture philanthropy
Development of curative treatments for glioblastoma (GBM) has been stagnant in recent decades largely because of significant financial risks. A portfolio-based strategy for the parallel discovery of breakthrough therapies can effectively reduce the financial risks of potentially transformative clini...
| Main Authors: | , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
Elsevier BV
2022
|
| Online Access: | https://hdl.handle.net/1721.1/144204 |
| _version_ | 1826202051001974784 |
|---|---|
| author | Siah, Kien Wei Xu, Qingyang Tanner, Kirk Futer, Olga Frishkopf, John J Lo, Andrew W |
| author2 | Sloan School of Management. Laboratory for Financial Engineering |
| author_facet | Sloan School of Management. Laboratory for Financial Engineering Siah, Kien Wei Xu, Qingyang Tanner, Kirk Futer, Olga Frishkopf, John J Lo, Andrew W |
| author_sort | Siah, Kien Wei |
| collection | MIT |
| description | Development of curative treatments for glioblastoma (GBM) has been stagnant in recent decades largely because of significant financial risks. A portfolio-based strategy for the parallel discovery of breakthrough therapies can effectively reduce the financial risks of potentially transformative clinical trials for GBM. Using estimates from domain experts at the National Brain Tumor Society (NBTS), we analyze the performance of a portfolio of 20 assets being developed for GBM, diversified across different development phases and therapeutic mechanisms. We find that the portfolio generates a 14.9% expected annualized rate of return. By incorporating the adaptive trial platform GBM AGILE in our simulations, we show that at least one drug candidate in the portfolio will receive US Food and Drug Administration (FDA) approval with a probability of 79.0% in the next decade. |
| first_indexed | 2024-09-23T12:01:05Z |
| format | Article |
| id | mit-1721.1/144204 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T12:01:05Z |
| publishDate | 2022 |
| publisher | Elsevier BV |
| record_format | dspace |
| spelling | mit-1721.1/1442042023-01-23T20:55:55Z Accelerating glioblastoma therapeutics via venture philanthropy Siah, Kien Wei Xu, Qingyang Tanner, Kirk Futer, Olga Frishkopf, John J Lo, Andrew W Sloan School of Management. Laboratory for Financial Engineering Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science Massachusetts Institute of Technology. Operations Research Center Development of curative treatments for glioblastoma (GBM) has been stagnant in recent decades largely because of significant financial risks. A portfolio-based strategy for the parallel discovery of breakthrough therapies can effectively reduce the financial risks of potentially transformative clinical trials for GBM. Using estimates from domain experts at the National Brain Tumor Society (NBTS), we analyze the performance of a portfolio of 20 assets being developed for GBM, diversified across different development phases and therapeutic mechanisms. We find that the portfolio generates a 14.9% expected annualized rate of return. By incorporating the adaptive trial platform GBM AGILE in our simulations, we show that at least one drug candidate in the portfolio will receive US Food and Drug Administration (FDA) approval with a probability of 79.0% in the next decade. 2022-08-03T17:52:11Z 2022-08-03T17:52:11Z 2021 2022-08-03T17:47:59Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/144204 Siah, Kien Wei, Xu, Qingyang, Tanner, Kirk, Futer, Olga, Frishkopf, John J et al. 2021. "Accelerating glioblastoma therapeutics via venture philanthropy." Drug Discovery Today, 26 (7). en 10.1016/J.DRUDIS.2021.03.020 Drug Discovery Today Creative Commons Attribution 4.0 International license https://creativecommons.org/licenses/by/4.0/ application/pdf Elsevier BV Elsevier |
| spellingShingle | Siah, Kien Wei Xu, Qingyang Tanner, Kirk Futer, Olga Frishkopf, John J Lo, Andrew W Accelerating glioblastoma therapeutics via venture philanthropy |
| title | Accelerating glioblastoma therapeutics via venture philanthropy |
| title_full | Accelerating glioblastoma therapeutics via venture philanthropy |
| title_fullStr | Accelerating glioblastoma therapeutics via venture philanthropy |
| title_full_unstemmed | Accelerating glioblastoma therapeutics via venture philanthropy |
| title_short | Accelerating glioblastoma therapeutics via venture philanthropy |
| title_sort | accelerating glioblastoma therapeutics via venture philanthropy |
| url | https://hdl.handle.net/1721.1/144204 |
| work_keys_str_mv | AT siahkienwei acceleratingglioblastomatherapeuticsviaventurephilanthropy AT xuqingyang acceleratingglioblastomatherapeuticsviaventurephilanthropy AT tannerkirk acceleratingglioblastomatherapeuticsviaventurephilanthropy AT futerolga acceleratingglioblastomatherapeuticsviaventurephilanthropy AT frishkopfjohnj acceleratingglioblastomatherapeuticsviaventurephilanthropy AT loandreww acceleratingglioblastomatherapeuticsviaventurephilanthropy |